Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Calls For Cautions for ILD in Patients Receiving Statins
May 24, 2010
- Otsuka HD: Sales of Healthcare Business Up 5.6%
May 24, 2010
- GAMMAGARD Improves Cognitive Function in AD Patients in PII: Baxter
May 24, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (1)
May 24, 2010
- Gaslon Accelerates Gastric Ulcer Healing after HP Infection
May 24, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? - Part 2 (2)
May 24, 2010
- Humira Achieves Clinical Remission Rate of 17.7% in 24 Weeks: PMS Data
May 24, 2010
- Janssen, Takeda to Copromote VELCADE in Japan
May 24, 2010
- Equa Can Become 1st-Choice DPP-4 Inhibitor: Prof. Kadowaki
May 24, 2010
- Santen Launches Tafluprost in South Korea
May 24, 2010
- Proper Use of Topical Steroids Should Be Promoted: Prof. Horio
May 24, 2010
- Torii to Boost Sales to ¥50 Bil. by FY2012
May 17, 2010
- Eisai Applies for Reflux Esophagitis for Pariet
May 17, 2010
- Treatment Cost Holds Key in Selection of ARB/CCB Combinations: Dr Ogihara
May 17, 2010
- METI Presents Report on Pharma Industry Promotion
May 17, 2010
- Abbott Japan Applies for Kaletra for Once Daily Treatment
May 17, 2010
- Chugai to Educate Top Oncology MRs
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (1)
May 17, 2010
- DSP's Eslicarbazepine Not Approved by FDA
May 17, 2010
- How Will Distribution Practice Be Improved Following Pricing System Reform? (2)
May 17, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…